CMV antigenemia, CMV disease, and regeneration of A2-NLV–specific CD8+ T lymphocytes in CMV-seropositive SCT recipients
| Patient (type of SCT) . | Donor CMV serology . | Onset of CMV antigenemia3-150 . | No. of GCV treatment courses . | CMV disease (day of onset)3-150 . | A2-NLV–specific CD8+ T lymphocytes . | |||
|---|---|---|---|---|---|---|---|---|
| No. in SCT3-151 . | Peak % in blood3-152 . | Peak no. in blood3-153 . | Follow-up3-150 . | |||||
| 1 (S) | Neg | 47 | 1 | — | < 0.1 | 14.2 (59)3-150 | 155 (90)3-150 | 365 |
| 2 (U) | Neg | 25 | 3 | — | < 0.1 | 2.1 (293) | 14 (293) | 365 |
| 3 (U) | Neg | 55 | 3 | 106 | < 0.1 | < 0.1 | < 1 | 270 |
| 4 (U) | Neg | 22 | 6 | 253 | < 0.1 | 0.2 (92) | < 1 | 270 |
| 5 (S) | Neg | 25 | 4 | 236 | < 0.1 | 0.2 (82) | 2 (82) | 238 |
| 6 (S) | Pos | 38 | 3 | 38 | < 0.1 | < 0.1 | < 1 | 367 |
| 7 (S) | Pos | 49 | 2 | — | 3.5 | 0.7 (54) | 2 (54) | 181 |
| 8 (S) | Pos | — | 0 | — | 11.3 | 3.4 (89) | 17 (89) | 355 |
| 9 (S) | Pos | 18 | 1 | — | 0.8 | 2.9 (346) | 113 (346) | 346 |
| 10 (U) | Pos | 17 | 0 | — | 2.2 | 3.3 (61) | 40 (61) | 181 |
| 11 (U) | Pos | 74 | 3 | — | 1.0 | 5.3 (84) | 124 (358) | 358 |
| 12 (S) | Pos | 24 | 1 | — | < 0.1 | 5.4 (180) | 36 (180) | 180 |
| 13 (S) | Pos | — | 0 | — | 3.6 | 0.5 (59) | 2 (94) | 365 |
| 14 (U) | Pos | 143 | 0 | — | 0.8 | 3.8 (178) | 19 (178) | 339 |
| 15 (S) | Pos | 357 | 1 | — | < 0.1 | 0.2 (180) | 1 (94) | 370 |
| 16 (S) | Pos | — | 0 | — | 0.2 | 0.2 (123) | < 1 | 181 |
| 17 (S) | Pos | 130 | 1 | — | NT | 1.3 (60) | 2 (180) | 180 |
| 18 (S) | Pos | — | 0 | — | NT | 4.3 (59) | 5 (97) | 270 |
| Patient (type of SCT) . | Donor CMV serology . | Onset of CMV antigenemia3-150 . | No. of GCV treatment courses . | CMV disease (day of onset)3-150 . | A2-NLV–specific CD8+ T lymphocytes . | |||
|---|---|---|---|---|---|---|---|---|
| No. in SCT3-151 . | Peak % in blood3-152 . | Peak no. in blood3-153 . | Follow-up3-150 . | |||||
| 1 (S) | Neg | 47 | 1 | — | < 0.1 | 14.2 (59)3-150 | 155 (90)3-150 | 365 |
| 2 (U) | Neg | 25 | 3 | — | < 0.1 | 2.1 (293) | 14 (293) | 365 |
| 3 (U) | Neg | 55 | 3 | 106 | < 0.1 | < 0.1 | < 1 | 270 |
| 4 (U) | Neg | 22 | 6 | 253 | < 0.1 | 0.2 (92) | < 1 | 270 |
| 5 (S) | Neg | 25 | 4 | 236 | < 0.1 | 0.2 (82) | 2 (82) | 238 |
| 6 (S) | Pos | 38 | 3 | 38 | < 0.1 | < 0.1 | < 1 | 367 |
| 7 (S) | Pos | 49 | 2 | — | 3.5 | 0.7 (54) | 2 (54) | 181 |
| 8 (S) | Pos | — | 0 | — | 11.3 | 3.4 (89) | 17 (89) | 355 |
| 9 (S) | Pos | 18 | 1 | — | 0.8 | 2.9 (346) | 113 (346) | 346 |
| 10 (U) | Pos | 17 | 0 | — | 2.2 | 3.3 (61) | 40 (61) | 181 |
| 11 (U) | Pos | 74 | 3 | — | 1.0 | 5.3 (84) | 124 (358) | 358 |
| 12 (S) | Pos | 24 | 1 | — | < 0.1 | 5.4 (180) | 36 (180) | 180 |
| 13 (S) | Pos | — | 0 | — | 3.6 | 0.5 (59) | 2 (94) | 365 |
| 14 (U) | Pos | 143 | 0 | — | 0.8 | 3.8 (178) | 19 (178) | 339 |
| 15 (S) | Pos | 357 | 1 | — | < 0.1 | 0.2 (180) | 1 (94) | 370 |
| 16 (S) | Pos | — | 0 | — | 0.2 | 0.2 (123) | < 1 | 181 |
| 17 (S) | Pos | 130 | 1 | — | NT | 1.3 (60) | 2 (180) | 180 |
| 18 (S) | Pos | — | 0 | — | NT | 4.3 (59) | 5 (97) | 270 |
CMV, cytomegalovirus; A2-NLV, NLVPMVATV peptide presented by HLA-A2; SCT, stem cell transplant; GCV, ganciclovir; S, HLA-matched sibling donor; U, HLA-matched unrelated donor; NT, not tested.
Day after SCT.
Number of A2-NLV-specific CD8+ T cells × 103/kg body weight of the recipient.
Peak percentage of A2-NLV-specific CD8+ T cells (expressed as fraction of total CD8+ T cell); day on which peak percentage was observed (in parentheses).
Peak absolute number of A2-NLV-specific CD8+ T cells × 103/μL; day on which peak absolute number was observed (in parentheses).